<?xml version="1.0" encoding="UTF-8"?>
<p>Conflicts of Interest: FS has served on the advisory boards for Abbvie, Janssen, MSD, Sanofi, and Takeda. GP received consultancy fees from Alphasigma. VP is on the scientific advisory board of Actial Farmaceutica Srl, Italy. DP received speaker fees from AbbVie, MSD, Takeda, Janssen, and Pfizer. GC is a consultant for and has received food and beverage compensation from Cook Medical, Boston Scientific, and Olympus. AG reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE, and Sanofi S.p.A, personal fees for acting as a speaker for Takeda S.p.A, AbbVie, and Sandoz S.p.A, and personal fees for acting on advisory boards for VSL3 and Eisai. IB is a consultant for Apollo Endosurgery, Cook Medical, and Boston Scientific; is a board member for Endo Tools; research grant recipient from Apollo Endosurgery; and has received food and beverage compensation from Apollo Endosurgery, Cook Medical, Boston Scientific, and Endo Tools. AA has received consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Ferring, Gilead, Janssen, Lilly, MSD, Mylan, Pfizer, Samsung Bioepis, Sandoz, and Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Biogen, Ferring, Giliead, Janssen, MSD, Mitsubishi-Tanabe, Nikkiso, Pfizer, Sandoz, Samsung Bioepis, Takeda; and research grants from MSD, Pfizer, Takeda. All the other authors have no conflicts of interest to declare.</p>
